Compare Direxion Daily Semiconductor Bear 3X Shares (SOXS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bear 3X Shares vs Vertex Pharmaceuticals Incorporated — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $34.39 (market cap $1.96B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 65.1× Direxion Daily Semiconductor Bear 3X Shares's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bear 3X Shares for 11 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SOXS | VRTX | |
|---|---|---|
Market Cap | $1.96B | $127.55B |
Volume | 113,512,541 | 1,487,944 |
Sector | Leveraged / Inverse | Health |
52-Week High | $988.00 | $557.96 |
52-Week Low | $29.62 | $407.37 |
Typical Hold Time | 11 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, surged 10.23% to $33.78 amid semiconductor sector volatility. The technical outlook remains bearish with moving averages signaling continued downward pressure, while oscillators show neutral momentum. Recent news highlights SOXS benefiting from semiconductor sell-offs, though analysts caution it's suited only for short-term tactical trades due to extreme volatility and structural decay inherent in leveraged inverse ETFs.
As a leveraged inverse ETF, SOXS carries significant risks including daily rebalancing costs and time decay, making it unsuitable for long-term holdings. The fund thrives during semiconductor downturns but faces headwinds from persistent AI hardware demand. Investors should recognize this as a speculative trading instrument rather than a fundamental investment vehicle.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
